Cyllene Therapeutics Presents Interim Data from Phase 1b/2a Clinical Trial Showing EG110A Reduced Urinary Episodes in Patients with Spinal Cord Injury at the International Continence Society (ICS) ConferenceParis and New York, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cyllene Therapeutics SAS (“Cyllene Tx”), a leader in site-specific, non-systemic DNA medicines for the treatment of prevalent chronic neurological disorders, today announced presentation of interim clinical data from the first two dose cohorts of its Phase 1b/2a trial showing that treatment with EG110A resulted in consistent and clinically relevant reductions in urinary incontinence episodes up to 52 weeks in people with spinal cord injury (“SCI”) with neurogenic detrusor overactivity (“NDO”). This debilitating and prevalent bladder disorder is characterized by uncontrolled urinary incontinence. The data, presented at the 56th International Continence Society Annual Meeting in Maastricht, the Netherlands, also showed EG110A to be well tolerated, with no severe drug related side effects or dose-limiting toxicity.
Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline ExpansionParis, July 07, 2026 (GLOBE NEWSWIRE) -- Cyllene Therapeutics, formerly known as EG 427, today announced the successful closing of a €33 million Series C financing led by new investors GordonMD Global Investments® LP (“GordonMD”) and M Ventures. Existing investors including Andera Partners SAS, Bpifrance Investissement through its InnoBio 3 Fund, L.P. and Lamond Ventures LLC also participated in the round.
